PapersPMID:35889747
Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.
What moved
1 findingHow to read these marks →“After normalization with baseline, Figure 4B shows a significant decrease in serum IL-6 level at 1, 3, and 6 months of low- and standard-dose Arthrospira consumption (* p < 0.05, ** p < 0.01, *** p < 0.001, compared to control).”
- Study
- RCT
- Interests
- Industry funded
- Dose studied
- 3 g daily or 6 g daily as add-on to nucleos(t)ide analogue, 6 months
- Population
- Adults aged 20 to 75 with chronic hepatitis B on nucleos(t)ide analogues for at least one year with undetectable HBV DNA; nucleos(t)ide analogue continued in all arms (background); 60 randomised to control, 3 g/day or 6 g/day Arthrospira, 56 retained; low and standard dose groups reported together against control
Study record
- Design
- randomised controlled trial
- Species
- human / mixed
- Population
- Chronic hepatitis B patients receiving nucleos(t)ide analogue for at least one year with undetectable HBV DNA
- Participants
- 60
- Comparator
- no treatment
- Duration
- 183 days
- Endpoints measured
- 30